HUP0100926A2 - Benzilpiperazinil- és benzilpiperidiniletanon-származékok, előállításuk és alkalmazásuk dopamin D4 receptor antagonistaként - Google Patents
Benzilpiperazinil- és benzilpiperidiniletanon-származékok, előállításuk és alkalmazásuk dopamin D4 receptor antagonistakéntInfo
- Publication number
- HUP0100926A2 HUP0100926A2 HU0100926A HUP0100926A HUP0100926A2 HU P0100926 A2 HUP0100926 A2 HU P0100926A2 HU 0100926 A HU0100926 A HU 0100926A HU P0100926 A HUP0100926 A HU P0100926A HU P0100926 A2 HUP0100926 A2 HU P0100926A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- atom
- alkyl
- hydrogen
- oxygen
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- HOJGUDWNFKNCPF-UHFFFAOYSA-N 3-phenyl-1-piperidin-1-ylpropan-1-one Chemical class C1CCCCN1C(=O)CCC1=CC=CC=C1 HOJGUDWNFKNCPF-UHFFFAOYSA-N 0.000 title 1
- 229940124243 Dopamine D4 receptor antagonist Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004434 sulfur atom Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- MHGRPEADXUSKAT-UHFFFAOYSA-N 2-(1-benzylpiperidin-4-yl)acetaldehyde Chemical class C1CC(CC=O)CCN1CC1=CC=CC=C1 MHGRPEADXUSKAT-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005529 alkyleneoxy group Chemical group 0.000 abstract 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical group C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
A találmány új, szubsztituált 2-(4-benzilpiperazin-1-il)- és 2-(1-benzil-piperidin-4-il)etanon-származékokra és ilyen vegyületekettartalmazó gyógyászati készítményekre vonatkozik. A találmány továbbáaz említett új vegyületeknek pszichotikus rendellenességek, ígypéldául skizofrénia és más központi idegrendszeri megbetegedésekmegelőzésére vagy kezelésére alkalmas gyógyászati készítményekelőállításánál való alkalmazására vonatkozik. A találmány szerintivegyületek (I) általános képletében Y jelentése oxigén- vagy kénatom;Z jelentése nitrogénatom vagy metincsoport; R1; R2 és R3 egymástólfüggetlenül hidrogén- vagy halogénatomot vagy hidroxi-, alkoxi-,alkil-, trifluormetil- vagy trifluormetoxicsoportot jelent; R4 és R4'egymástól függetlenül hidrogénatomot vagy alkilcsoportot jelent vagyegyütt 3-7-tagú gyűrűt alkotnak azzal a szénatommal, amelyhezkapcsolódnak; R5 jelentése hidrogénatom vagy alkil-, alkoxi- vagyalkiltiocsoport; R6 jelentése hidrogénatom vagy alkilcsoport; vagy R5és R6 együtt alkilén-, alkilénoxi- vagy alkiléntiocsoportotjelentenek, ahol az oxigén- vagy kénatom a fenilgyűrűvel közvetlenülszomszédos, továbbá R5 és R6 5-9-tagú gyűrűt alkothat azokkal aszénatomokkal, amelyekhez kapcsolódnak; és R7, R8, R9, R10 és R11egymástól függetlenül hidrogénatomot vagy alkilcsoportot jelent - Atalálmány kiterjed továbbá a (VIIa) és (VIIb) általános képletűköztitermékekre is. Ezek képletében X oxigén- vagy kénatomot vagymetiléncsoportot jelent, m értéke 0, 1, 2, 3 vagy 4 és L jelentésekilépő csoport. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3098798A | 1998-02-26 | 1998-02-26 | |
| PCT/US1999/004309 WO1999043670A1 (en) | 1998-02-26 | 1999-02-26 | Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d4 receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0100926A2 true HUP0100926A2 (hu) | 2001-09-28 |
| HUP0100926A3 HUP0100926A3 (en) | 2003-03-28 |
Family
ID=21857045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0100926A HUP0100926A3 (en) | 1998-02-26 | 1999-02-26 | Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d4 receptor antagonists |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1068193A1 (hu) |
| JP (1) | JP2002504549A (hu) |
| KR (1) | KR20010041341A (hu) |
| CN (1) | CN1293669A (hu) |
| AU (1) | AU2881499A (hu) |
| CA (1) | CA2321830A1 (hu) |
| HU (1) | HUP0100926A3 (hu) |
| IL (1) | IL137930A0 (hu) |
| NO (1) | NO20004271L (hu) |
| PL (1) | PL342597A1 (hu) |
| WO (1) | WO1999043670A1 (hu) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6084098A (en) | 1999-02-26 | 2000-07-04 | Neurogen Corporation | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands |
| US6355644B1 (en) | 1999-06-14 | 2002-03-12 | Neurogen Corporation | Benzylpiperazinyl-indolinylethanones |
| WO2000076967A1 (en) * | 1999-06-14 | 2000-12-21 | Neurogen Corporation | Benzylpiperazinyl-indolinylethanones |
| EP1177792A3 (en) | 2000-07-27 | 2002-10-23 | Pfizer Products Inc. | Dopamine D4 Ligands for the treatment of novelty-seeking disorders |
| KR100394083B1 (ko) | 2000-12-04 | 2003-08-06 | 학교법인 성신학원 | 도파민 ｄ3 및 ｄ4 수용체의 선택적 활성을 지닌 신규4,5-디히드로이소옥사졸릴알킬피페라진 유도체와, 이의제조방법 |
| KR100394086B1 (ko) | 2000-12-04 | 2003-08-06 | 한국과학기술연구원 | 도파민 ｄ3 및 ｄ4 수용체의 선택적 활성을 지닌 신규이소옥사졸릴알킬피페라진 유도체와, 이의 제조방법 |
| CN1181065C (zh) | 2002-05-08 | 2004-12-22 | 上海医药工业研究院 | 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用 |
| DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
| GB201106817D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| ES2860695T3 (es) | 2013-11-18 | 2021-10-05 | Forma Therapeutics Inc | Composiciones de tetrahidroquinolina como inhibidores de bromodominio BET |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| HUE056297T2 (hu) | 2013-12-20 | 2022-02-28 | Astex Therapeutics Ltd | Biciklikus heterociklusos vegyületek és ezek terápiában történõ alkalmazása |
| CN103966340B (zh) * | 2014-05-26 | 2015-09-16 | 宁波大学 | 一种用于辅助诊断阿尔茨海默病的检测试剂盒及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2863752A (en) * | 1953-10-30 | 1958-12-09 | Monsanto Chemicals | Herbicides |
| US2909523A (en) * | 1957-10-11 | 1959-10-20 | American Cyanamid Co | Substituted piperazines and method of preparing the same |
| US3268584A (en) * | 1961-08-28 | 1966-08-23 | Monsanto Co | Herbicidal alpha-haloacetanilides |
| GB1065801A (en) * | 1964-02-19 | 1967-04-19 | Nippon Soda Co | N-substituted fluoroacetamides and their use as insecticides |
| DE2604224A1 (de) * | 1976-02-04 | 1977-08-11 | Hoechst Ag | Herbizide mittel |
| JPS5318540A (en) * | 1976-08-02 | 1978-02-20 | Nippon Nohyaku Co Ltd | Alpha-chloroacetamides and their use |
| HU201757B (en) * | 1988-03-11 | 1990-12-28 | Pfizer | Process for producing pyrroloquinoline-, acridine-, benzoxazine-, benzthiazine-, indolobenzoxazine-, benzazepine and pyrrolophenothiazine carboxamides and pharmaceutical compositions comprising same |
| EP0934932A4 (en) * | 1996-08-22 | 2002-06-26 | Meiji Seika Kaisha | CHINOLINE DERIVATIVES AND PSYCHOTROPES MEDIUM |
| ATE287878T1 (de) * | 1996-08-23 | 2005-02-15 | Neurosearch As | Disubstituierte morpholin-, oxazepin- oder thiazepinderivate, deren herstellung und verwendung als dopamin-d4-rezeptorantagonisten |
| AU6256198A (en) * | 1997-02-19 | 1998-09-09 | Hoechst Marion Roussel, Inc. | Benzamides having dopamine d4 receptor affinity |
| WO1999021848A2 (en) * | 1997-10-27 | 1999-05-06 | Neurogen Corporation | Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands |
| JP2001521935A (ja) * | 1997-10-31 | 2001-11-13 | ニューロゲン コーポレイション | ３−アミノアルキルアミノ−２ｈ−１，４−ベンゾキシアジン及び３−アミノアルキルアミノ−２ｈ−１，４−ベンゾチアジン：ドーパミン受容体サブタイプ特定の配位子 |
-
1999
- 1999-02-26 EP EP99909657A patent/EP1068193A1/en not_active Withdrawn
- 1999-02-26 WO PCT/US1999/004309 patent/WO1999043670A1/en not_active Application Discontinuation
- 1999-02-26 PL PL99342597A patent/PL342597A1/xx not_active Application Discontinuation
- 1999-02-26 KR KR1020007009454A patent/KR20010041341A/ko not_active Application Discontinuation
- 1999-02-26 CA CA002321830A patent/CA2321830A1/en not_active Abandoned
- 1999-02-26 JP JP2000533426A patent/JP2002504549A/ja active Pending
- 1999-02-26 HU HU0100926A patent/HUP0100926A3/hu unknown
- 1999-02-26 CN CN99804026A patent/CN1293669A/zh active Pending
- 1999-02-26 IL IL13793099A patent/IL137930A0/xx unknown
- 1999-02-26 AU AU28814/99A patent/AU2881499A/en not_active Abandoned
-
2000
- 2000-08-25 NO NO20004271A patent/NO20004271L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1293669A (zh) | 2001-05-02 |
| NO20004271D0 (no) | 2000-08-25 |
| CA2321830A1 (en) | 1999-09-02 |
| NO20004271L (no) | 2000-10-25 |
| JP2002504549A (ja) | 2002-02-12 |
| EP1068193A1 (en) | 2001-01-17 |
| PL342597A1 (en) | 2001-06-18 |
| IL137930A0 (en) | 2001-10-31 |
| AU2881499A (en) | 1999-09-15 |
| WO1999043670A1 (en) | 1999-09-02 |
| KR20010041341A (ko) | 2001-05-15 |
| HUP0100926A3 (en) | 2003-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0100926A2 (hu) | Benzilpiperazinil- és benzilpiperidiniletanon-származékok, előállításuk és alkalmazásuk dopamin D4 receptor antagonistaként | |
| HUP9902471A2 (hu) | Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0204245A2 (hu) | Új N-aza-biciklo-amid-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP9901820A2 (hu) | 4-Amino-pirimidin-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra | |
| NO994452D0 (no) | Substituerte 4-arylmetylen-2-imino-2,3-dihydrotiazoler og derivater, og deres farmasöytiske anvendelse | |
| HUP9902148A2 (hu) | Új 2,3-diszubsztituált-4(3H)-kinazolinonok | |
| SE9302080D0 (sv) | New compounds | |
| HUP0303164A2 (hu) | Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0302264A2 (hu) | Dopamin D3 receptorok modulátoraiként felhasználható tetrahidrobenzazepin-származékok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0200469A2 (hu) | Szulfamátszármazékok alkalmazása az impulzus kontrol zavarok kezelésére | |
| BG104561A (en) | Aryl fused azapolycyclic compounds | |
| HUP0204458A2 (hu) | Alfa-2-antagonista hatású kinolinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| ATE266013T1 (de) | 1-phenyl-4-benzylpiperazine: spezifische liganden für den dopamin rezeptor (d4) | |
| DE69831446T2 (de) | Chinazolin-4-on AMPA Antagonisten | |
| IL107869A0 (en) | Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them | |
| HUP0301811A2 (hu) | Hipolipidémiás és hipokoleszterinémiás hatású szubsztituált pirrolszármazékok, azokat tartalmazó gyógyszerkészítmények, eljárás elżállításukra, köztitermékek és alkalmazásuk | |
| HUP0201356A2 (hu) | Ösztrogén agonisták/antagonisták alkalmazása depresszió kezelésére vagy a kognitív funkció romlásának megelőzésére alkalmas gyógyászati készítmény előállítására | |
| YU64400A (sh) | Aril fuzirana azapoliciklična jedinjenja | |
| KR920019796A (ko) | 1-(피리도[3,4-b]-1,4-옥사지닐-4-일)-1H-인돌, 이의 중간체 및 이들의 제조방법, 및 약제로서의 이들의 용도 | |
| HUP0303270A2 (hu) | Antidepresszáns hatású izoxazolinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0000489A2 (hu) | 5-HT-Receptor affinitású szulfonamidszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| MA27137A1 (fr) | Derives substitues d'alkylaminopyridazinone, procedes de preparation et composition pharmaceutique les contenant | |
| DE69624459T2 (de) | Kondensierte indan-derivate und ihre salze | |
| DE69210959D1 (de) | Benzo(b)thiophen-2-carboxamide zur Behandlung von Krankheiten des Zentralnervensystems | |
| HUP0400744A2 (hu) | Piridoindolon származékok felhasználása rákellenes gyógyszerek előállítására |